Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 13/20 | 0.47 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | MMP12 | P39900 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.37 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17243686 | 0.75 | GAA (0.54) | DUTDDB1CRBNPOLBHSD17B10 | |
| SCHEMBL5796877 | 0.72 | CRBN (0.49) | DUTDDB1CRBNPOLBHSD17B10 | |
| SCHEMBL8151927 | 0.71 | SMN1; SMN2 (0.54) | DUTDDB1CRBNMMP1MMP2 | |
| SCHEMBL10475657 | 0.70 | ALDH1A1 (0.36) | DUTCRBNPOLBHSD17B10PKM | |
| SCHEMBL6722429 | 0.70 | DUT (0.59) | DUTDDB1CRBN | |
| SCHEMBL5801201 | 0.70 | CRBN (0.46) | DUTDDB1CRBNPOLBHSD17B10 | |
| SCHEMBL3993881 | 0.69 | CRBN (0.45) | DUTDDB1CRBNPOLBHSD17B10 | |
| SCHEMBL2800300 | 0.68 | DUT (0.59) | DUTDDB1CRBN | |
| SCHEMBL5797006 | 0.68 | CRBN (0.44) | DUTDDB1CRBNPOLBHSD17B10 | |
| SCHEMBL19359274 | 0.66 | DUT (0.62) | DUTDDB1CRBNKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1491201-B1 | Methods of reducing toxicity of 5-fluorouracil with acylated pyrimidine nucleosides | WELLSTAT THERAPEUTICS CORP (US) | 2006-03-22 | — | — | EP | claimed |
| EP-0831849-A4 | METHODS OF REDUCING TOXICITY OF CHEMOTHERAPEUTIC AND ANTIVIRAL AGENTS WITH ACYLATED PYRIMIDINE NUCLEOSIDES | WELLSTAT THERAPEUTICS CORP (US) | 2003-03-26 | — | — | EP | claimed |
| US-6344447-B2 | ADMINISTERING MIXTURE OF NUCLEOSIDES; ANTICANCER AGENT | PRO-NEURON, INC. | 2002-02-05 | — | — | US | claimed |
| US-20010025032-A1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | VON BORSTEL REID W (US) | 2001-09-27 | — | — | US | claimed |
| US-5968914-A | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides | PRO-NEURON, INC. (US) | 1999-10-19 | — | — | US | claimed |
| EP-0831849-A1 | METHODS OF REDUCING TOXICITY OF CHEMOTHERAPEUTIC AND ANTIVIRAL AGENTS WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1998-04-01 | — | — | EP | claimed |
| WO-1996040165-A1 | METHODS OF REDUCING TOXICITY OF CHEMOTHERAPEUTIC AND ANTIVIRAL AGENTS WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1996-12-19 | — | — | WO | claimed |
| EP-3851030-B1 | MEDICAL DEVICE FOR ANALYTE MONITORING | LABRADOR DIAGNOSTICS LLC (US) | 2024-01-17 | — | — | EP | disclosed |
| US-20230034174-A1 | IMMUNOMODULATING TUMOR NECROSIS FACTOR RECEPTOR 25 (TNFR25) AGONISTS, ANTAGONISTS, AND IMMUNOTOXINS | UNIVERSITY OF MIAMI | 2023-02-02 | — | — | US | disclosed |
| US-11395846-B2 | Immunomodulating tumor necrosis factor receptor 25 (TNFR25) agonists, antagonists, and immunotoxins | UNIVERSITY OF MIAMI (US) | 2022-07-26 | — | — | US | disclosed |
| CN-114173780-A | Compounds for reducing the deleterious activity of genes containing extended nucleotide repeats | 小利兰·斯坦福大学托管委员会 | 2022-03-11 | — | — | CN | disclosed |
| US-20220062233-A1 | Compounds for the Reduction of the Deleterious Activity of Extended Nucleotide Repeat Containing Genes | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2022-03-03 | — | — | US | disclosed |
| EP-3897634-A1 | COMPOUNDS FOR THE REDUCTION OF THE DELETERIOUS ACTIVITY OF EXTENDED NUCLEOTIDE REPEAT CONTAINING GENES | The Board of Trustees of the Leland Stanford Junior University (US) | 2021-10-27 | — | — | EP | disclosed |
| WO-2002070750-A2 | METHOD OF DETERMINING DIHYDROPYRIMIDINE DEHYDROGENASE GENE EXPRESSION | RESPONSE GENETICS, INC. (US) | 2002-09-12 | — | — | WO | disclosed |
| US-20020123620-A1 | Method of determining dihydropyrimidine dehydrogenase gene expression | CANCER GENETICS, INC. | 2002-09-05 | — | — | US | disclosed |
| US-6344447-B2 | ADMINISTERING MIXTURE OF NUCLEOSIDES; ANTICANCER AGENT | PRO-NEURON, INC. | 2002-02-05 | — | — | US | disclosed |
| US-20010025032-A1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | VON BORSTEL REID W (US) | 2001-09-27 | — | — | US | disclosed |
| US-5968914-A | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides | PRO-NEURON, INC. (US) | 1999-10-19 | — | — | US | disclosed |
| EP-0831849-A1 | METHODS OF REDUCING TOXICITY OF CHEMOTHERAPEUTIC AND ANTIVIRAL AGENTS WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1998-04-01 | — | — | EP | disclosed |
| WO-1996040165-A1 | METHODS OF REDUCING TOXICITY OF CHEMOTHERAPEUTIC AND ANTIVIRAL AGENTS WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220062233-A1 | Compounds for the Reduction of the Deleterious Activity of Extended Nucleotide Repeat Containing Genes | NSUN2, RTCB, RRM2B | DUT 38/4885DDB1 24/4885CRBN 1724/4885 |
| US-20010025032-A1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | TYMP, NUDT1, UNG | DUT 6/4885DDB1 132/4885CRBN 4393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.